[Seite 136↓]

Literaturverzeichnis

(1) Krebsatlas der Bundesrepublik Deutschland. 3 ed. Berlin, Heidelberg, New York: Springer, 1997.

(2) Autier P, Dore JF. Influence of sun exposures during childhood and during adulthood on melanoma risk. EPIMEL and EORTC Melanoma Cooperative Group. European Organisation for Research and Treatment of Cancer. Int J Cancer 1998; 77(4):533-537.

(3) Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172:902-908.

(4) Buttner P, Garbe C, Bertz J, Burg G, d'Hoedt B, Drepper H et al. Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification. Cancer 1995; 75(10):2499-2506.

(5) MacKie RM, Aitchison T, Sirel JM, McLaren K, Watt DC. Prognostic models for subgroups of melanoma patients from the Scottish Melanoma Group database 1979-86, and their subsequent validation. Br J Cancer 1995; 71(1):173-176.

(6) McGovern VJ, Shaw HM, Milton GW. Prognosis in patients with thin malignant melanoma: influence of regression. Histopathology 1983; 7(5):673-680.

(7) Cooper PH, Wanebo HJ, Hagar RW. Regression in thin malignant melanoma. Microscopic diagnosis and prognostic importance. Arch Dermatol 1985; 121(9):1127-1131.

(8) Garbe C, Buttner P, Bertz J, Burg G, d'Hoedt B, Drepper H et al. Primary cutaneous melanoma. Prognostic classification of anatomic location. Cancer 1995; 75(10):2492-2498.

(9) Garbe C, Buttner P, Bertz J, Burg G, d'Hoedt B, Drepper H et al. Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer 1995; 75(10):2484-2491.

(10) Slingluff CL, Stidham KR, Ricci WM, Stanley WE, Seigler HF. Surgical management of regional lymph nodes in patients with melanoma. Ann Surg 1994; 219(2):120-130.

(11) Joseph E, Brobeil A, Glass F, Glass J, Messina J, Deconti R et al. Results of complete lymph node dissection in 83 melanoma patients with positive sentinel nodes. Ann Surg Oncol 1998; 5(2):119-125.

(12) Hohenberger W, Göhl J, Altendorf HA, Meyer T. Lymphknotendissektionen beim malignen Melanom. Chirurg 1996; 67(8):779-787.

(13) Balch CM, Houghton AN, Sober AJ, Soong SJ. Cutaneous Melanoma. 3 ed. St. Louis: Quality Medical Publishing, Inc., 1998.

(14) Lee YM. Loco-regional recurrent melanoma: I Natural history. Cancer Treat Rev 1980; 7:59-72.

(15) Lee YM. Loco-regional primary and recurrent melanoma: III. Update of natural history and non-systemic treatments (1980-1987). Cancer Treat Rev 1988; 15:135-162.

(16) Lang NP, Stair JM, Degges RD, Thompson C, Garner H, Baker GF et al. Melanoma today does not require radical surgery. Am J Surg 1984; 148:723-726.

(17) Urist MM, Balch CM, Soong SJ, Shaw HM, Milton GW, Maddox WA. The influence of surgical margins and prognostic factors predicting the risk of local recurrence in 3445 patients with primary cutaneous melanoma. Cancer 1985; 55:1398-1402.

(18) Cascinelli N, Bufalino R, Marolda R, Belli F, Nava M, Galluzzo D et al. Regional non-nodal metastasesof cutaneous melanoma. Eur J Surg Oncol 1986; 12:175-180.

(19) Hill S, Thomas JM. Use of the carbon dioxide laser to manage cutaneous metastases from malignant melanoma. Br J Surg 1996; 83(4):509-512.

(20) Tilgen W. Therapie des malignen Melanoms: Derzeitiger Stand und Perspektiven. In: Macher E, Kolde G, Bröcker EB, editors. Jahrbuch der Dermatologie 1994/1995 - Tumoren und Haut. Zülpich: Biermann-Verlag, 1995: 310-323.

(21) Tilgen W, Kaufmann R. Malignes Melanom. Forum DKG 1995; 10:310-323.

(22) Coindre J-M, Terrier P, Binh Bui N, Bonichon F, Collin F, Le Doussal V et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma: a study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol 1996; 14:869-877.

(23) Gaynor JJ, Tan CC, Casper ES, Collin CF, Friedrich C, Shiu MH et al. Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: A study of 423 adults. J Clin Oncol 1992; 10:1317-1329.

(24) Levine EA. Prognostic factors in soft tissue sarcoma. Semin Surg Oncol 1999; 17(1):23-32.

(25) Guillou L, Coindre J-M, Bonichon F, Binh Bui N, Terrier P, Collin F et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997; 15:350-362.

(26) Pisters PW, Harrison LB, Leung DH, Woodruff JM, Casper ES, Brennan MF. Long-term results of a prospective randomised trial of adjuvant brachytheapy in soft tissue sarcoma. J Clin Oncol 1996; 14(3):859-868.

(27) Goodland JR, Fletcher CDM, Smith MA. Surgical resection of primary soft-tissue sarcoma. Journal of Bone and Joint Surgery 78-B, 658-661. 1996.

(28) Peiper M, Zurakowski D, Zornig C. Survival in primary soft tissue sarcoma of the extremities and trunk. Langenbecks Arch Chir 1997; 382:203-208.

(29) Noria S, Davis A, Kandel R, Levesque J, O'Sullivan B, Wunder J et al. Residual disease following unplanned excision of a soft-tissue sarcoma of an extremity. J Bone Joint Surg 1996; 78-A(5):650-655.

(30) Zornig C, Peiper M, Schröder S. Re-excision of soft tissue sarcoma after inadequate initial operation. Br J Surg 1995; 82:278-279.

(31) Davis A, Kandel RA, Wunder JS, Unger R, Meer J, O'Sullivan B et al. The impact of residual disease on local recurrence in patients treated by initial unplanned resection for soft tissue sarcoma of the extremity. J Surg Oncol 1999; 66:81-87.

(32) Brennan MF. Chirurgische Therapie und Prognose des Weichteilsarkoms. Chirurg 1993; 64:449-454.

(33) Klopp CT, Alford TC, Bateman J. Fractional intra-arterial cancer chemotherapy with methyl-bis-amine hydrochloride. Ann Surg 1950; 132:811-832.

(34) Sullivan RD, Jones R, Schnabel TG, Shorey JM. The treatment of human cancer with intra-arterial nitrogen mustard (methylbis (2-chloroethyl) amine hydrochloride) utilizing a simplified catheter technique. Cancer 1953; 6:121-134.

(35) Ryan RF, Krementz ET, Creech O, Winblad JN, Chamblee W, Cheek H. Selected perfusion of isolated viscera with chemotherapeutic agents using extracorporeal circuit. Surg Forum 1957; 8:158-161.

(36) Creech O, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958; 148:616-631.

(37) Krementz ET, Creech O, Ryan RF, Wickstrom J. Treatment of malignant tumors of the extremities by perfusion with chemotherapeutic agents. J Bone Joint Surg 1959; 41:977-987.

(38) Cavaliere R, Ciocatto EC, Giovanella BC, Heidelberger C, Johnson RO, Margottini M et al. Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer 1967; 20:1351-1381.

(39) Giovanella BC, Stehlin JS, Williams LJ. Selective lethal effect of supranormal temperatures on mouse sarcoma cells. Cancer Res 1973; 33:2658-2578.

(40) Stehlin JS, Giovanella BC, deIpolyi PD, Muenz LR, Anderson RF. Results of hyperthermic perfusion for melanoma of the extremities. Surg Gynecol Obstet 1975; 140:339-348.

(41) Goss P, Parsons PG. The effect of hyperthermia and melphalan on survival of human fibroblast strains and melanoma cell lines. Cancer Res 1977; 37:152-156.

(42) Krementz ET. Regional perfusion - Current sophistication, what next ? Cancer 1986; 57:416-432.

(43) Wieberdink J, Benckhuysen C, Braat RP, Van Slooten EA, Olthuis GAA. Dosimetry in isolation perfusion of the limbs by assessement of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18:905-910.

(44) Shiu MH, Knapper WH, Fortner JG, Yeh S, Horowitz G, Schnog J et al. Regional isolated limb perfusion of melanoma intransit metastases using mechlorethamine (nitrogen mustard). J Clin Oncol 1986; 4:1819-1826.

(45) Di Filippo F, Calabro A, Giannarelli D, Carlini S, Cavaliere F, Moscarelli F. Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer 1989; 63:2551-2561.

(46) Fletcher WS, Woltering EA, Moseley HS, Bos G, Lebredo L, Brown D et al. Hyperthermic isolation limb perfusion (HILP) in the management of extremity melanoma and sarcoma with particular reference to the dosage, pharmacokinetics, and toxicity of cisplatin. Cancer Treat Res 1993; 62:241-244.

(47) Hoekstra HJ, Schraffordt Koops H, De Vries LGEJ, Van Weerden TW, Oldhoff J. Toxicity of hyperthermic isoalted limb perfusion with cisplatin for recurrent melanoma of the lower extremity after previous perfusion. Cancer 1993; 72:1224-1229.

(48) Klein ES, Ben-Ari GY. Isolation perfusion with cisplatin for malignant melanoma of the limbs. Cancer 1987; 59:1068-1071.

(49) Thompson JF, Gianoutsos MP. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 1992; 16:227-233.

(50) Ariyan S, Mitchell MS, Kirkwood JM. Regional isolated perfusion of high risk melanoma of the extremities with imidazole carboxamide. Surg Gynecol Obstet 1984; 158:238-242.

(51) Didolkar MS, Fitzpatrick JL, Jackson AJ, Johnston GS. Toxicity and complications of vascular isolation and hyperthermic perfusion with imidazole carboxamide (DTIC) in melanoma. Cancer 1986; 57:1961-1966.

(52) Aigner K, Schwemmle K. Technik der isolierten Extremitätenperfusion. Langenbecks Arch Chir 1983; 359:113-122.

(53) Vaglini M, Belli F, Marolda R, Prada A, Santinami M, Cascinelli N. Hyperthermic antiblastic perfusion with DTIC in stage IIIA-IIIAB melanoma of the extremities. Eur J Surg Oncol 1987; 13:127-129.

(54) Eilber FR, Guiliano AE, Huth J, Mirra J, Morton DL. Limb salvage for high-grade soft tissue sarcomas of the extremity: experience at the University of California, Los Angeles. Cancer Treat Symp 1985; 3:49-57.

(55) Hoekstra HJ, Schraffordt Koops H, Molenaar WM, Oldhoff J. Results of regional perfusion in the treatment of malignant soft tissue tumors of the extremities. Cancer 1987; 60:1703-1707.

(56) Kettelhack C, Willecke F, Kraus T, Schlag PM. Isolated hyperthermic limb perfusion for soft tissue sarcoma. Acta Chir Austriaca 1993; 25:257-259.

(57) Cavaliere R, Cavaliere F, Deraco M, Di Filippo F, Santinami M, Monica S et al. Hyperthermic antiblastic perfusion in the treatment of stage IIIa-IIIab melanoma patients. Comparison of two experiences. Melanoma Res 1994; 4,Suppl 1:5-11.

(58) Santinami M, Belli F, Cascinelli N, Rovini D, Vaglini M. Seven years experience with hyperthermic perfusions in extracorporeal circulation for melanoma of the extremities. J Surg Oncol 1989; 42:201-208.

(59) Kroon BBR, Klaase JM, van Geel AN, Eggermont AMM. Application of hyperthermia in regional isolated perfusion for melanoma of the limbs. Reg Cancer Treat 1992; 4:223-226.

(60) Klaase JM, Kroon BBR, Eggermont AMM, van Geel AN, Schraffordt Koops H, Oldhoff J et al. A retrospective comparative study evaluating the results of mild hyperthermic versus controlled normothermic perfusion for recurrent melanoma of the extremities. Eur J Cancer 1995; 31A:58-63.

(61) Göhl J, Hohenberger W. Die regionale hypertherme Perfusion - Therapiekonzept und Langzeitergebnisse. Langenbecks Arch Chir Suppl Kongressbd 1992;494-501.

(62) Meyer T, Göhl J, Haas C, Hohenberger W. Hyperthermic isolated limb perfusion - 23 years experience and improvement of results by modification of technique. Onkologie 1998; 21:198-202.

(63) Taber SW, Polk HC. Mortality, major amputation rates, and leukopenia after isolated limb perfusion with phenylalanine mustard for the treatment of melanoma. Ann Surg Oncol 1997; 4(5):440-445.

(64) Würl P, Eichfeld U, Pauer HD, Rose U, Dralle H. Hyperthermic regional cytostatic limb perfusion in patients with malignant melanoma - comparison between methotrexate and melphalan. Int J Surg Sci 1995; 2(5):241-244.

(65) Lienard D, Ewalenko P, Delmotte JJ, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10:52-60.

(66) Lienard D, Eggermont AMM, Schraffordt Koops H, Kroon BBR, Rosenkaimer F, Autier P et al. Isolated perfusion of the limb with high-dose tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res 1994; 4 (S1):21-26.

(67) Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that induces necrosis of tumors. Proc Natl Acad Sci U S A 1975; 72:3666-3670.

(68) Watanabe N, Niitsu Y, Umeno H, Kuriyama H, Neda H, Yamauchi N et al. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res 1988; 48:2179-2183.

(69) Haranaka K, Satomi N, Sakurai A. Antitumor activity of murine tumor necrosis factor (TNFα) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer 1984; 34:263-267.

(70) Frater-Schröder M, Risau W, Hallmann R, Gautschi P, Böhlen P. Tumor necrosis factor type-α, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci USA 1987; 84:5277-5281.

(71) Sato N, Goto T, Haranaka K, Satomi N, Nariuchi H, Mano-Hirano Y et al. Actions of tumor necrosis factor on cultured vascular endothelial cells: morphologic modulation, growth inhibition, and cytotoxicity. J Natl Cancer Inst 1986; 76:1113-1121.

(72) Stolpen AH, Guinan EC, Fiers W, Pober JS. Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers. Am J Pathol 1986; 23:16-24.

(73) Kettelhack C, Robaye B, Morandini R, Mosselmans R, Ghanem G, Lejeune F. Induction of apoptosis in human endothelial cells by TNF and interferon-gamma. Annals of Hematology 67, A156. 1993.

(74) Plaat BE, Molenaar WM, Mastik MF, Koudstaal J, van-den-Berg E, Koops HS et al. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in patients with locally advanced soft tissue sarcomas: treatment response and clinical outcome related to changes in proliferation and apoptosis. Clin Cancer Res 1999; 5(7):1650-1657.

(75) Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physio Rev 1990; 70:427-451.

(76) Renard N, Lienard D, Lespagnard L, Eggermont A, Heimann R, Lejeune F. Early endothelium activation and polymorphnuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumor necrosis factor alpha (rTNFα). Int J Cancer 1994; 57:656-663.

(77) Renard N, Nooijen P, Schalkwijk L, de Waal R, Eggermont A, Lienard D et al. Intravascular thrombocyte aggregation and erythrostasis are associated with necrosis in melanoma metastasis after perfusion with a high dosis tumor necrosis factor- α (TNFα). Eur Cytokine Netw 1994; 5:219.

(78) Lejeune F, Lienard D, Eggermont A, Schraffordt Koops H, Rosenkaimer F, Gérain J et al. Rationale for using TNFalpha and chemotherapy in regional therapy of melanoma. J Cell Biochem 1994; 56:52-61.

(79) Olieman AF, van-Ginkel RJ, Hoekstra HJ, Mooyaart EL, Molenaar WM, Koops HS. Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Ann Surg Oncol 1997; 4(1):64-69.

(80) Fraker DL, Alexander HR, Andrich MP, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon-gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 1996; 14:479-489.

(81) Zwaveling JH, Maring JK, Moshage H, van Ginkel RJ, Hoekstra HJ, Schraffordt Koops H et al. Role of nitric oxide in recombinant tumor necrosis factor-α—induced circulatory shock: a study in patients treated for cancer with isolated limb perfusion. Critical Care Med 1996; 24(11):1806-1810.

(82) Zwaveling JH, Maring JK, Clarke FL, van Ginkel RJ, imburg PC, oekstra HJ et al. High plasma tumor necrosis factor (TNF)-α concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-α, interferon-γ, and melphalan. Critical Care Med 1996; 24(5):765-770.

(83) Fawcett WJ, Hill S, Sheldon J, Williams TR, Thomas JM, Riches P et al. Hemodynamic changes and circulating recombinant tumor necroses factor-α concentrations in a patient undergoing isolated limb perfusion. Critical Care Med 1993; 21:796-800.

(84) Gerain J, Lienard D, Ewalenko P, Lejeune FJ. High serum levels of TNF-alpha after its administration for isolation perfusion of the limb. Cytokine 1992; 4:585-591.

(85) Thom AK, Alexander HR, Andrich MP, Barker WC, Rosenberg SA, Fraker DL. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon-gamma, and melphalan. J Clin Oncol 1995; 13:264-273.

(86) Sorkin P, Abu-Abid S, Lev D, Gutman M, Aderka D, Halpern P et al. Systemic leakage and side effects of tumor necrosis factor alpha administererd via isolated limb perfusion can be manipulated by flow rate adjustment. Arch Surg 1995; 130:1079-1084.

(87) al-Nawas B, Shah PM. Procalcitonin in patients with and without immunosuppression and sepsis. Infection 1996; 24(6):434-436.

(88) Nylen ES, Snider RH, Thompson KA, Rohatgi P, Becker KL. Pneumonitis-associated hyperprocalcitoninemia. Am J Med Sci 1996; 312(1):12-18.

(89) Hatherill M, Jones G, Lim E, Tibby SM, Murdoch IA. Procalcitonin aids diagnosis of adrenocortical failure. Lancet 1997; 350:1749-1750.

(90) Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohoun C. High serum procalcitonin concentrations in patients with sepsis and infections. Lancet 1993; 341:515-518.

(91) Franklin HR, Schraffordt Koops H, Oldhoff J, Czarnetzki BM, Macher E, Kroon BBR et al. To perfuse or not to perfuse? A retrospective comparative study to evaluate the effect of adjuvant isolated regional perfusion in patients with stage I extremity melanoma with a thickness of 1.5 mm or greater. J Clin Oncol 1988; 6:701-708.

(92) Edwards MJ, Soong SJ, Boddie AW, Balch CM, McBride CM. Isolated limb perfusion for localized melanoma of the extremity. Arch Surg 1990; 125:317-321.

(93) Koops HS, Vaglini M, Suciu S, Kroon BB, Thompson JF, Gohl J et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 1998; 16(9):2906-2912.

(94) Rosin RD, Westbury C. Isolated limb perfusion for malignant melanoma. Practitioner 1980; 224:188-198.

(95) Lejeune FJ, Deloof T, Ewalenko P, Frühling J, Jabri M, Mathieu M et al. Objective regression of unexcised melanoma in-transit metastases after hyperthermic isolation perfusion of the limbs with melphalan. Rec Res Cancer Res 1983; 86:268-276.

(96) Storm FK, Morton DL. Value of therapeutic hyperthermic limb perfusion in advanced and recurrent melanoma of the lower extremity. Am J Surg 1985; 150:32-35.

(97) Skene AI, Bulman AS, Williams TR, Thomas JM, Westbury G. Hyperthermic isolated limb perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb. Br J Surg 1990; 77:765-767.

(98) Klaase JM, Kroon BBR, van Geel AN, Eggermont AMM, Franklin HR, Hart AAM. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 1994; 115:39-45.

(99) Thompson JF, Hunt JA, Shannon KF, Kam PC. Frequency and duration of remission after isolated limb perfusion for melanoma. Archives of Surgery 132[8], 903-907. 1997.

(100) Kettelhack C, Kraus T, Hupp T, Manner M, Schlag P. Hyperthermic limb perfusion for malignant melanoma and soft tissue sarcoma. Eur J Surg Oncol 1990; 16:370-375.

(101) Schraffordt Koops H, Oldhoff J, Oosterhuis JW, Beekhuis H. Isolated regional perfusion in malignant melanoma of the extremities. World J Surg 1987; 11:527-533.

(102) Lejeune FJ, Lienard D, El Douaihy M, Vadoud Seyedi J, Ewalenko P. Results of 206 isolated limb perfusions for malignant melanoma. Eur J Surg Oncol 1989; 15:510-519.

(103) Eggermont AMM, Schraffordt Koops H, Klausner JM, Kroon BBR, Schlag PM, Lienard D et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. Ann Surg 1996; 224(6):756-765.

(104) Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47(1):207-214.

(105) Sijens PE, Eggermont AM, van-Dijk PV, Oudkerk M. 31P magnetic resonance spectroscopy as predictor of clinical response in human extremity sarcomas treated by single dose TNF-alpha + melphalan isolated limb perfusion. NMR Biomed 1995; 8(5):215-224.

(106) Fontijne WPJ, Mook PH, Schraffordt Koops H, Oldhoff J, Wildevuur CRH. Improved tissue perfusion during pressure regulated hyperthermic regional perfusion. Cancer 1985; 55:1455-1461.

(107) Gutman M, Inbar M, Lev-Shlush D, Abu-Abid S, Mozes M, Chaitchik S et al. High-dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer 1997; 97:1129-1137.

(108) Kroon BBR. Regional isolation perfusion in melanoma of the limbs; accomplishments, unsolved problems, future. Eur J Surg Oncol 1988; 14:101-110.

(109) Sprenger H-J, Markwardt J, Schlag PM. Ouantitative Leckbestimmung bei der isolierten Extremitätenperfusion. NuklMed 1994; 33:248-253.

(110) Manner M, Sinn H, Bubeck H, Kettelhack C, Schlag P. Verbesserte intraoperative Leckkontrolle bei der isolierten Zytostatikaperfusion von Extemitätentumoren. Langenbecks Arch Chir 1990; 375:208-213.

(111) Lienard D, Lejeune FJ, Ewalenko P. In-transit metastases of malignant melanoma treated by high dose rTNF-alpha in combination with interferon-gamma and melphalan in isolation perfusion. World J Surg 1992; 16:234-240.

(112) Haier J, Hohenberger P, Schlag PM. Kontinuierliches Monitoring kardiozirkulatorischer Effekte der isolierten hyperthermen Extremitätenperfusion mit rhTNFalpha/Melphalan mit der Thermodilutionsmethode. Langenbecks Arch Chir Suppl Kongressbd 1995;251-257.

(113) Haier J, Hohenberger P, Schlag PM. Quantification of skeleton muscle damage after isolated limb perfusion by determination of myoglobin and creatinkinase. European Journal of Surgical Oncology 20. 1994.

(114) Trojani M, Contesso G, Coindre JM, Rouesse J, Bui NB, de-Mascarel A et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 1984; 33(1):37-42.

(115) Salzer-Kuntschik M. Klassifikation und Grading der Weichgewebstumoren. Chirurg 1993; 64:435-442.

(116) van-Unnik JA, Coindre JM, Contesso C, Albus LC, Schiodt T, Sylvester R et al. Grading of soft tissue sarcomas: experience of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1993; 29A(15):2089-2093.

(117) Minor DR, Allen RE, Alberts D, Peng Y, Tardelli G, Hutchinson J. A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma. Cancer 1985; 55:2638-2644.

(118) Klaase JM, Kroon BBR, van Geel AN, Eggermont AMM, Franklin HR, Van Dongen JA. Is there an indication for a double perfusion schedule with melphalan for patients with recurrent melanoma of the limbs? Melanoma Res 1994; 4,Suppl 1:13-16.

(119) Kroon BBR, Klaase JM, Van de Merwe SA, Van Dongen JA, Van der Zee J. Results of a double perfusion schedule using high-dose hyperthermia and melphalan sequentially for recurrent melanoma of the limbs: a pilot study. Reg Cancer Treat 1992; 4:305-308.

(120) Feldman AL, Alexander-HR J, Bartlett DL, Fraker DL, Libutti SK. Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma. Ann Surg Oncol 1999; 6(6):562-567.

(121) Bartlett DL, Ma G, Alexander HR, Libutti SK, Fraker DL. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer 1997; 80(11):2084-2090.

(122) Meyer T, Göhl J, Hohenberger W. Lokoregionäre Rezidive von Extremitätenmelanomen nach hyperthermer Extremitätenperfusion: Sind Re-Perfusionen sinnvoll? Langenbecks Arch Chir Suppl Kongressbd 1998; 115:1452-1454.

(123) Lejeune FJ, Lienard D, Eggermont AM, Schraffordt Koops H. Isolation perfusion with rTNFα + rIFNγ + melphalan for in transit metastases of malignant melanoma. Update of a pilot study. European Journal of Cancer 29A, S117. 1993.

(124) Lienard D, Eggermont AM, Koops HS, Kroon B, Towse G, Hiemstra S et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999; 9(5):491-502.

(125) Hill S, Fawcett WJ, Sheldon J, Soni N, Williams T, Thomas JM. Low-dose tumor necrosis factor α and melphalan in hyperthermic isolated limb perfusion. Br J Surg 1993; 80:995-997.

(126) Vaglini M, Santinami M, Manzi R, Inglese MG, Santoro N, Persiani L et al. Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumor necrosis factor-alpha (TNF-α), melphalan and interferon-gamma (IFN-γ). Dose-finding experience at the National Cancer Institute of Milan. Melanoma Res 1994; 4:35-38.

(127) Pitcher ME, Ramanathan RC, Fish S, A'Hern RP, Thomas JM. Outcome of treatment for limb and limb girdle sarcomas at the Royal Marsden Hospital. Eur J Surg Oncol 2000; 26:548-551.

(128) Pisters PW, Leung DH, Woodruff JM, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996; 14:1679-1689.

(129) Lewis JJ, Leung D, Heslin M, Woodruff JM, Brennan MF. Association of local recurrence with subsequent survival in extremity soft tissue sarcoma. J Clin Oncol 15, 646-652. 1997.

(130) Brennan MF. The enigma of local recurrence. Ann Surg Oncol 1997; 4(1):1-12.

(131) Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998; 16(1):197-203.

(132) Lise M, Rossi CR, Alessio S, Foletto M. Multimodality treatment of extra-visceral soft tissue sarcomas M0: state of the art and trends. Eur J Surg Oncol 1995; 21:125-135.

(133) Rosenberg SA, Tepper J, Glatstein E, Costa J, Baker A, Brennan M et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982; 196(3):305-315.

(134) Pollock RE, Karnell LH, Menck HR, Winchester DP. The National Cancer Data Base report on soft tissue sarcoma. Cancer 1996; 78:2247-2257.

(135) Junginger Th, Kettelhack C, Schönfelder M, Saeger HD, Rieske H, Krummenauer F et al. Therapeutische Strategien bei malignen Weichteiltumoren - Ergebnisse der Weichteiltumor-Registerstudie der CAO. Chirurg 2001; 72:138-148.

(136) Willet CG, Schiller AL, Suit HD, Mankin HJ, Rosenberg A. The histologic response of soft tissue sarcoma to radiation therapy. Cancer 1987; 60:1500-1504.

(137) Hew L, Kandel R, Davis A, O'Sullivan B, Catton C, Bell R. Histological necrosis in soft tissue sarcoma following preoperative radiation. J Surg Oncol 1994; 57:11-114.

(138) Suit HD, Mankin HJ, Wood WC, Gebhardt MC, Harman DC, Rosenberg A et al. Treatment of the patient with stage M0 soft tissue sarcoma. J Clin Oncol 1988; 6:854-862.

(139) Sauer R, Schuchardt U, Hohenberger W, Wittekind C, Papadopoulos T, Grabenbauer GG et al. Neoadjuvante Radiochemotherapie von Weichteilsarkomen. Optimierung der lokalen funktionserhaltenden Tumorkontrolle. Strahlenther Onkol 1999; 175(6):259-266.

(140) Cheng EY, Dusenbery KE, Winters MR, Thompson RC. Soft tissue sarcomas: preoperative versus postoperative radiotherapy. J Surg Oncol 1996; 61:90-99.

(141) Bujko K, Suit HD, Springfield DS, Convery K. Wound healing after preoperative radiation for sarcoma of soft tissues. Surg Gynecol Obstet 1993; 176:124-134.

(142) Casper ES, Gaynor JJ, Harrison LB, Panicek DM, Hajdu SI, Brennan MF. Preoperative and postoperative adjuvant combination chemotherapy for adults with high grade soft tissue sarcoma. Cancer 1994; 73:1644-1651.

(143) Pezzi CM, Pollock RE, Evans HL, Lorigan JG, Pezzi TA, Benjamin RS et al. Preoperative chemotherapy for soft-tissue sarcomas of the extremities. Ann Surg 1990; 211(4):476-481.

(144) Rosen G, Eilber F, Eckhardt J, Holmes C, Forscher CA, Lowenbraun S et al. Präoperative Chemotherapie in der Behandlung von Weichteilsarkomen. Chirurg 1993; 64:443-448.

(145) Issels RD, Bosse D, Starck M, Abdel-Rahman S, Jauch KW, Schilberg FW et al. Weichteiltumoren: Indikation und Ergebnisse der Hyperthermie. Chirurg 1993; 64:461-467.

(146) Issels RD, Abdel-Rahman S, Falk MH, Salat C, Ochmann O, Wilmanns W et al. Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) followed by surgery and radiation in primary and recurrent high-risk soft tissue sarcomas (HR-STS) of adults. Proceedings of the American Society of Clinical Oncology . 1999.

(147) Wanebo HJ, Temple WJ, Popp MB, Constable W, Aron B, Cunningham SL. Preoperative regional therapy for extremity sarcoma. Cancer 1995; 75:2299-2306.

(148) Nijhuis P, Pras E, Seijfer D, Molenaar W, Schraffordt Koops H, Hoekstra HJ. Morbidity of a combined modality therapy of intra-arterial doxorubicin, neoadjuvant radiotherapy and surgery for locally advanced high grade soft tissue saromas (STS) of the extremities. European Journal of Cancer 33 Suppl 8, S113. 1997.

(149) Lejeune FJ, Lienard D, Ewalenko P. Hyperthermic isolation perfusion of the limbs with cytostatics after surgical excision of sarcomas. World J Surg 1988; 12:345-348.

(150) Klaase JM, Kroon BBR, Benckhuijsen C, van Geel AN, Albus-Lutter CE, Wieberdink J. Results of regional perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer 1989; 64:616-621.

(151) Pommier RF, Moseley HS, Cohen J, Huang CS, Townsend R, Fletcher WS. Pharmacokinetics, toxicity, and short-term results of cisplatin hyperthermic isolated limb perfusion for soft-tissue sarcoma and melanoma of the extremities. Am J Surg 1988; 155:667-671.

(152) Di Filippo F, Calabrò AM, Cavallari A, Carlini S, Buttini GL, Moscarelli F et al. The role of hyperthermic perfusion as a first step in the treatment of soft tissue sarcoma of the extremities. World J Surg 1988; 12:332-339.

(153) Lehti PM, Moseley HS, Janoff K, Stevens K, Fletcher WS. Improved survival for soft tissue sarcoma of the extremities by regional hyperthermic perfusion, local excision and radiation therapy. Surg Gynecol Obstet 1986; 162:149-152.

(154) Schwarzbach M, Lehnert T, Willeke F, Hinz U, Herfarth C. Ergebnisse der isolierten hyperthermen Extremitätenperfusion bei Weichteilsarkomen im Rahmen eines multimodalen Behandlungskonzeptes. Chirurg 1996; 67(12):1237-1243.

(155) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92(3):205-216.

(156) Costa J, Wesley RA, Glatstein E, Rosenberg SA. The grading of soft tissue sarcomas. Results of a clinicohistopathologic correlation in a series of 163 cases. Cancer 1984; 53(3):530-541.

(157) Issakov J, Merimsky O, Gutman M, Kollender Y, Lev-Chelouche D, Abu-Abid S et al. Hyperthermic isolated limb perfusion with tumor necrosis factor-α and melphalan in advanced soft-tissue sarcomas: histopathological considerations. Ann Surg Oncol 2000; 7(1):155-159.

(158) Di-Filippo F, Rossi CR, Vaglini M, Azarelli A, Anzà A, Santinami M et al. Hyperthermic antiblastic perfusion with alpha tumor necrosis factor and doxorubicin for the treatment of soft tissue limb sarcoma in candidates for amputation: results of a phase I study. J Immunother 1999; 22(5):407-414.

(159) van-Ginkel RJ, Kole AC, Nieweg OE, Molenaar WM, Pruim J, Koops HS et al. L-[1-11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer. J Nucl Med 1999; 40(2):262-267.

(160) Griffiths JR, Cady E, Edwards RH, McCready VR, Wilkie DR, Wiltshaw E. 31P-NMR studies of a human tumour in situ [letter]. Lancet 1983; 1(8339):1435-1436.

(161) Nidecker AC, Muller S, Aue WP, Seelig J, Fridrich R, Remagen W et al. Extremity bone tumors: evaluation by P-31 MR spectroscopy. Radiology 1985; 157(1):167-174.

(162) Ross B, Marshall V, Smith M, Bartlett S, Freeman D. Monitoring response to chemotherapy of intact human tumours by 31P nuclear magnetic resonance. Lancet 1984; 1(8378):641-646.

(163) Semmler W, Gademann G, Bachert BP, Zabel HJ, Lorenz WJ, van-Kaick G. Monitoring human tumor response to therapy by means of P-31 MR spectroscopy. Radiology 1988; 166(2):533-539.

(164) Ng TC, Evanochko WT, Hirameto RM. 31-P NMR spectroscopy of in vivo tumors. J Magn Reson 1982; 49:271-286.

(165) Ng TC, Vijayakumar S, Majors AW, Thomas FJ, Meaney TF, Baldwin NJ. Response of a non-Hodgkin lymphoma to 60Co therapy monitored by 31P MRS in situ. Int J Radiat Oncol Biol Phys 1987; 13(10):1545-1551.

(166) Ng TC, Majors AW, Vijayakumar S, Baldwin NJ, Thomas FJ, Koumoundouros I et al. Human neoplasm pH and response to radiation therapy: P-31 MR spectroscopy studies in situ. Radiology 1989; 170(3 Pt 1):875-878.

(167) Semmler W, Gademann G, Schlag P, Bachert BP, Zabel HJ, Lorenz WJ et al. Impact of hyperthermic regional perfusion therapy on cell metabolism of malignant melanoma monitored by 31P MR spectroscopy. Magn Reson Imaging 1988; 6(3):335-340.

(168) Redmond OM, Stack JP, O'Connor NG, Carney DN, Dervan PA, Hurson BJ et al. 31P MRS as an early prognostic indicator of patient response to chemotherapy. Magn Reson Med 1992; 25(1):30-44.

(169) Koutcher JA, Ballon D, Graham M, Healey JH, Casper ES, Heelan R et al. 31P NMR spectra of extremity sarcomas: diversity of metabolic profiles and changes in response to chemotherapy. Magn Reson Med 1990; 16(1):19-34.

(170) Gustafson P, Rööser B, Rydholm A. Is local recurrence of minor importance for metastases in soft tissue sarcoma? Cancer 67, 2083-2086. 1991.

(171) Ueda T, Yoshikawa H, Mori S, Araki N, Myoui A, Kuratsu S et al. Influence of local recurrence on the prognosis of soft-tissue sarcomas. Journal of Bone and Joint Surgery 79-B, 553-557. 1997.

(172) Eggimann P, Chiolèro R, Chassot P-G, Lienard D, Gerain J, Lejeune F. Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs. Chest 1995; 107:1074-1082.

(173) Lejeune FJ. High dose recombinant tumor necrosis factor (rTNFα) administered by isolation perfusion for advanced tumors of the limbs: a model for biochemotherapy of cancer. Eur J Cancer 1995; 31A:1009-1016.

(174) Kettelhack C, Hohenberger P, Schlag PM. Die isolierte hypertherme Extremitätenperfusion beim malignen Melanom mit Melphalan und Tumornekrosefaktor. Dtsch Med Wochenschr 1997; 122:177-181.

(175) Goris RJA. MODS/SIRS: result of an overwhelming inflammatory response? World J Surg 1996; 20:418-421.

(176) Nathens AB, Marshall JC. Sepsis, SIRS, and MODS: what's in a name? World J Surg 1996; 20:386-391.

(177) Vaglini M, Belli F, Ammatuna M, Inglese MG, Manzi R, Prada A et al. Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon, and melphalan. Cancer 1994; 73:483-492.

(178) Olieman AF, Lienard D, Eggermont AM, Kroon BB, Lejeune FJ, Hoekstra HJ et al. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study. Arch Surg 1999; 134(3):303-307.

(179) Lev CD, Abu AS, Kollander Y, Meller I, Isakov J, Merimsky O et al. Multifocal soft tissue sarcoma: limb salvage following hyperthermic isolated limb perfusion with high-dose tumor necrosis factor and melphalan. J Surg Oncol 1999; 70(3):185-189.

(180) Zwaveling JH, Hoekstra HJ, Maring JK, van Ginkel RJ, Schraffordt Koops H, Smit AJ et al. Renal function in cancer patients treated with hyperthermic isolated limb perfusion with recombinant tumor necrosis factor-α and melphalan. Nephron 1997; 76:146-152.

(181) Hohenberger P, Haier J, Schlag PM. Rhabdomyolysis and renal function impairment after isolated limb perfusion - comparison between the effects of perfusion with rhTNF-alpha and a "triple-drug" regimen. Eur J Cancer 1997; 33(4):596-601.

(182) Stam TC, Swaak AJ, de-Vries MR, ten-Hagen TL, Eggermont AM. Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage. Ann Surg Oncol 2000; 7(4):268-275.

(183) Omlor G, Molter G, Meessen S, Gross G, Seyfert U, Feifel G. Kardiozirkulatorische Nebenwirkungen der hyperthermen Extremitätenperfusion. Langenbecks Arch Chir 1993; 378:17-20.

(184) Eggermont AMM, Schraffordt Koops H, Lienard D, Kroon BBR, van Geel AN, Hoekstra HJ et al. Isolated limb perfusion with high-dose tumor necrosis factor alpha in combination with interferon-gamma and melphalan for irresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996; 14(10):2653-2665.

(185) Sonneveld EJ, Vrouenraets BC, van-Geel BN, Eggermont AM, Klaase JM, Nieweg OE et al. Systemic toxicity after isolated limb perfusion with melphalan for melanoma. Eur J Surg Oncol 1996; 22(5):521-527.

(186) Aderka D, Sorkine P, Abu AS, Lev D, Setton A, Cope AP et al. Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion. Relevance to the pathophysiology of septic shock. J Clin Invest 1998; 101(3):650-659.

(187) Bone RC. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 1996; 125:680-687.

(188) Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Critical Care Med 1996; 24(7):1125-1128.

(189) Mulder AB, Zwaveling JH, Smid WM, Maring JK, van-Ginkel RJ, Girbes AR et al. Augmented procoagulant activity in cancer patients, treated with recombinant interferon-gamma in addition to recombinant tumor necrosis factor-alpha and melphalan. Thromb Haemost 1996; 76(6):897-901.

(190) Swaak AJG, Lienard D, Schraffordt Koops H, Lejeune FJ, Eggermont AMM. Effects of recombinant tumor necrosis factor (rTNF-alpha) in cancer. Observations on the acute phase protein reaction and immunoglobulin synthesis after high-dose recombinant TNF-alpha administration in isolated limb perfusions in cancer patients. Eur J Clin Invest 1993; 23:812-818.

(191) Schenk S, Lienard D, Gérain J, Baumgartner M, Lejeune FJ, Chiquet-Ehrismann R et al. Rapid increase in plasma tenascin-C concentration after isolated limb perfusion with high-dose tumor necrosis factor (TNF), interferon-gamma and melphalan for regionally advanced tumors. Int J Cancer 1995; 63:665-672.

  1. Quinn TD, Polk HC, Edwards MJ. Hyperthermic isolated limb perfusion increases circulating levels of inflammatory cytokines. Cancer Immunol Immunother 1995; 40:272-275.

(193) De Werra I, Jaccard C, Corradin SB, Chiolèro R, Yersin B, Gallati H et al. Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Critical Care Med 1997; 25(4):607-613.

(194) Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metabol 1994; 79:1605-1608.

(195) Kettelhack C, Hohenberger P, Schulze G, Kilpert B, Schlag PM. Induction of systemic serum procalcitonin and cardiocirculatory reactions after isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan. Crit Care Med 2000; 28(4):1040-1046.

(196) Klaase JM, Kroon BBR, van Geel AN, Eggermont AMM, Franklin HR. Systemic leakage during isolated limb perfusion for melanoma. Br J Surg 1993; 80:1124-1126.

(197) Lingam MK, Byrne DS, Aitchison T, MacKie RM, McKay AJ. A single centre's 10 year experience with isolated limb perfusion in the treatment of recurrent malignant melanoma of the limb. Eur J Cancer 1996; 32A(10):1668-1673.

(198) Ghussen F, Nagel K, Sturz J, Isselhard W. A modified dye dilution method to estimate leakage during regional isolated perfusoin of the extremity. Res Exp Med 1982; 180:179-187.

(199) Alexander C, Berberich R, Omlor G, Schmidt S. Measurement of blood leakage during isolation perfusion by 99mTc blood pool labelling. Reg Cancer Treat 1991; 3:312-315.

(200) Rauschecker HF, Foth H, Michaelis HC, Horst F, Gatzemeier W, Willenbrock C et al. Kinetics of melphalan leakage during hyperthermic isolation perfusion in melanoma of the limb. Cancer Chemother Pharmacol 1991; 27:379-384.

(201) Vrouenraets BC, Kroon BB, Ogilvie AC, van-Geel AN, Nieweg OE, Swaak AJ et al. Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Ann Surg Oncol 1999; 6(4):405-412.

(202) Schlag P, Kettelhack C. Zum Problem der operativen Behandlung von Patienten unter cytostatischer Chemotherapie. Chirurg 1989; 60:295-300.

(203) Kettelhack Ch, Balanou P, Schlag PM. Auswirkungen chemotherapeutischer Therapiekonzepte auf die Komplikationsrate chirurgischer Eingriffe. Onkologe 1998; 4:839-846.

(204) van Geel AN, Van Wijk J, Wieberdink J. Functional morbidity after regional isolated perfusion of the limb for melanoma. Cancer 1989; 63:1092-1096.

(205) Vrouenraets BC, Klaase JM, Nieweg OE, Kroon BB. Toxicity and morbidity of isolated limb perfusion. Semin Surg Oncol 1998; 14(3):224-231.

(206) Vrouenraets BC, Hart GA, Eggermont AM, Klaase JM, van-Geel BN, Nieweg OE et al. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J Am Coll Surg 1999; 188(5):522-530.

(207) Vrouenraets BC. Toxicity and morbidity of isolated limb perfusion. University of Amsterdam, 1997.

(208) Hohenberger P, Haier J, Kettelhack Ch, Schulze G, Schlag PM. Erfassung regionaler und systemischer Toxizität der isolierten hyperthermen Extremitätenperfusion mit Tumor-Nekrose-Faktor-alpha und Melphalan. Chirurg 1997; 68:914-920.

(209) Vrouenraets BC, Kroon BB, Klaase JM, Nieweg OE, van-Slooten GW, van-Dongen JA. Severe acute regional toxicity after normothermic or 'mild' hyperthermic isolated limb perfusion with melphalan for melanoma. Melanoma Res 1995; 5(6):425-431.

(210) Thompson JF, Lai DTM, Ingvar C, Kam PCA. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res 1994; 4,Suppl 1:45-50.

(211) Lai DT, Ingvar C, Thompson JF. The value of monitoring serum creatine phosphokinase following hyperthermic isolated limb perfusion for melanoma. Reg Cancer Treat 1993; 6:36-39.

(212) Hohenberger P, Finke LH, Schlag PM. Intracompartmental pressure during hyperthermic isolated limb perfusion for melanoma and sarcoma. Eur J Surg Oncol 1996; 22:147-151.

(213) Klaase JM, Kroon BB, van-Geel BN, Eggermont AM, Franklin HR, Hart GA. Patient- and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities. Am J Surg 1994; 167(6):618-620.

(214) Klaase JM, Kroon BBR, Beijnen JH, Van Slooten GW, Van Dongen JA. Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb. Br J Cancer 1994; 70:151-153.

(215) Norda A, Loos U, Sastry M, Goehl J, Hohenberger W. Pharmacokinetics of melphalan in isolated limb perfusion. Cancer Chemother Pharmacol 1999; 43(1):35-42.

(216) Fontijne WPJ, De Vries J, Mook PH, Elstrodt JM, Oosterhuis JW, Schraffordt Koops H et al. Improved tissue perfusion during pressure-regulated hyperthermic regional isolated perfusion in dogs. J Surg Oncol 1984; 26:69-76.

(217) Van der Zee J, Broekmeyer-Reurink MP, Van den Berg AP, van Geel BN, Jansen RFM, Kroon BBR et al. Temperature distribution and pH changes during hyperthermic regional isolation perfusion. Eur J Cancer Clin Oncol 1989; 25:1157-1163.

(218) Van de Merwe SA, Van den Berg AP, Kroon BBR, Van den Berge AW, Klaase JM, Van der Zee J. Modification of human tumor and normal tissue pH during hyperthermic and normothermic antiblastic regional isolation perfusion for malignant melanom: a pilot study. Int J Hyperthermia 1993; 9:205-217.

(219) Vrouenraets BC, Eggermont AMM, Klaase JM, van Geel BN, Van Dongen JA, Kroon BBR. Long-term neuropathy after regional isolated perfusion for melanoma of the limbs. Eur J Surg Oncol 1994; 20:681-685.

(220) Vrouenraets BC, Klaase JM, Kroon BBR, van Geel BN, Eggermont AMM, Franklin HR. Long-term morbiditiy after regional isolated perfusion with melphalan for melanoma of the limbs. Arch Surg 1995; 130:43-47.

(221) Vrouenraets BC, Keus RB, Nieweg OM, Kroon BB. Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis alpha +/- interferon gamma and melphalan in patients with irresectable soft tissue tumors. J Surg Oncol 1997; 65:88-94.

(222) Lin PP, Schupak KD, Boland PJ, Brennan MF, Healey JH. Pathologic femoral fracture after periosteal excision and radiation for the treatment of soft tissue sarcoma. Cancer 1998; 82(12):2356-2365.

(223) Alektiar KM, Zelefsky MJ, Brennan MF. Morbidity of adjuvant brachytherapy in soft tissue sarcoma of the extremity and superficial trunk. Int J Radiat Oncol Biol Phys 2000; 47(5):1273-1279.


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 4.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
07.06.2005